TBPH

Theravance Biopharma, Inc.

19.17

USD

TBPH Earnings Reports

Positive Surprise Ratio

TBPH beat 17 of 40 last estimates.

43%

Next Report

Date of Next Report

Feb 24, 2026

Estimate for Q4 25 (Revenue/ EPS)

$51.81M

$1.14

Implied change from Q3 25 (Revenue/ EPS)

+159.17%

+1528.57%

Implied change from Q4 24 (Revenue/ EPS)

+176.25%

-467.74%

Theravance Biopharma, Inc. earnings per share and revenue

On Nov 10, 2025, TBPH reported earnings of 0.07 USD per share (EPS) for Q3 25, beating the estimate of -0.13 USD, resulting in a 153.48% surprise. Revenue reached 19.99 million, compared to an expected 20.36 million, with a -1.81% difference. The market reacted with a +22.68% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 9 analysts forecast an EPS of 1.14 USD, with revenue projected to reach 51.81 million USD, implying an increase of 1528.57% EPS, and increase of 159.17% in Revenue from the last quarter.

FAQ

What were Theravance Biopharma, Inc.'s earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Theravance Biopharma, Inc. reported EPS of $0.07, beating estimates by 153.48%, and revenue of $19.99M, -1.81% below expectations.

How did the market react to Theravance Biopharma, Inc.'s Q3 2025 earnings?

The stock price moved up 22.68%, changed from $15.08 before the earnings release to $18.50 the day after.

When is Theravance Biopharma, Inc. expected to report next?

The next earning report is scheduled for Feb 24, 2026.

What are the forecasts for Theravance Biopharma, Inc.'s next earnings report?

Based on 9 analysts, Theravance Biopharma, Inc. is expected to report EPS of $1.14 and revenue of $51.81M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.